Catalyst Pharmaceuticals
Presença
Catalyst Pharmaceuticals é uma das ...
Catalyst Pharmaceuticals é uma empresa listada sob o símbolo CPRX (US).
Executivos
Veja o organograma con seus 17 executivos principais
Biografias mais buscadas da Catalyst Pharmaceuticals
- Patrick McEnany, Non-Executive Chairman of the Board
- Richard Daly, Director and Chief Executive Officer
- David Tierney, Director
Recentes movimentos de executivos em Catalyst Pharmaceuticals
- Michael Kalb ingressará na Companhia como Executive Vice President and Chief Financial Officer em 1 de jan. de 2024 (Notícia publicada em 5 de dezembro de 2023).
- Alicia Grande, Vice President, Chief Financial Officer and Treasurer, irá se aposentar em 31 de dez. de 2023 (Notícia publicada em 5 de dezembro de 2023).
- Richard Daly atualmente Member of the Board, será promovido a Director and Chief Executive Officer em 1 de jan. de 2024 (Notícia publicada em 19 de outubro de 2023).
Clique aqui para ver outras movimentos em Catalyst Pharmaceuticals
Criar um alerta
para seguir os movimentos de executivos da Catalyst Pharmaceuticals.
Farmacêutica
Catalyst Pharmaceuticals possui 1.867 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
- Frontier Medicines acaba de anunciar uma arrecadação de fundos de 80 milhões de dólares. (publicado em 27 de fevereiro de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Catalyst Pharmaceuticals
- Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update : Catalyst Pharmaceutical
- Press Releases : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE® : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023 : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE® : Catalyst Pharmaceutical
- Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer : Catalyst Pharmaceutical
- View more press releases Close
Redes sociais sobre Catalyst Pharmaceuticals
- Catalyst Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Catalyst Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Patrick McEnany 
Ligue para a Catalyst Pharmaceuticals em +1 305...
